November 2011

JAMA: CCTA use in CAD evaluations leads to higher costs ()
Lancet: Self-monitoring warfarin can cut risk of bleeding events ()
RSNA: Stress EKG or echo followed by CCTA is most cost effective for CAD evals ()
FDA agrees to review apixaban for AF patients ()
NEJM: New surveillance methods needed for approved anticoagulants ()
AIM: Hospitals rarely meet time-to-transfer goal for patients needing PCI ()
RSNA: Using CT in the ED for acute chest pain requires a strategic plan ()
RSNA: Healthcare reformthe good, the bad & the ugly ()
RSNA: Best practices for communicating dose risks to patients ()
RSNA: CTA20 years old, but not quite grown up ()
AIM: 1 in 10 PCI patients readmitted within 30 days ()
Feature: Neuroimaging may unlock secrets of PTSD + TBI ()
Vioxx becomes a pain; Merck to pay $950M for illegal marketing ()
ACC/AHA release new guidelines for HCM ()
2012: Year of Cost-conscious Care ()
RSNA feature: CTA shows gender-specific heart attack risk ()
Study: Post-op cardiothoracic surgeon management could save millions ()
2012: Time for the Resourceful ()
JAMA: Surgery improves survival for infective endocarditis patients with HF ()
Gender Disparities Persist with CAD ()
Study: DTI sheds new light on sports-related head injuries ()
Cardiac Implantable Devices Stamping Out Infections ()
JACC: CAS can help curb carotid artery occlusions ()
CV Leaders Get Lean and Sigma-fied ()
ACC Corner | Innovation vs. FDA Process: At Odds? ()
JACC: Treating hypertrophic cardiomyopathy invasively results in survival benefit ()
JAMA: 1 in 4 ICD patients don't receive optimal medical therapy ()
Lancet: Patients benefit from LDL-C lowering strategies long-term ()
EMA updates dabigatran label due to increased fatal bleeds ()
Erasmus fires Poldermans over research misconduct ()
JAMA: Tripling Plavix maintenance dose benefits some poor metabolizers ()
RSNA feature: Tales from the cryptwhen structured reporting goes awry ()
Medtronic offloads Physio-Control for $487M ()
AHA Q&A: Holmes parses out whether ATLAS will change practice ()
AHA video: Critics take high aim at AIM-HIGH; Boden responds ()
AIM: With carotid stenting, less should be more for asymptomatic patients ()
AHA video: Exercise equates to stenting outcomes for PAD ()
AHA video: Kastrati talks ISAR trials, potential bivalirudin uptick in EU ()
AHA: Crestor, Lipitor both shine in high-dose SATURN trial ()
AHA video: New trial design for discharged pulmonary embolism patients suggested ()
AHA: Pharmacist intervention ups prescriptions, but not HF outcomes ()
AHA: PALLAS shows dronedarone is harmful in permanent AF patients ()
AHA video: Remote program as effective as in-person for obesity ()
AHA video: Consent reform can make patient informed consumers ()
Thomson Reuters taps top 50 hospitals for heart care ()
TCT: The do's and don'ts of avoiding complications during TAVI ()
AHA video: Cell therapy finding its niche in cardiac care ()
TCT: The must-haves when starting a TAVI program ()
AHA video: RF ablation may be first-line option for paroxysmal AF ()
AHA video: Surgical backup for elective PCI? Randomized trial says no need ()
AHA: TRA-CER tracks increased ACS bleeds with vorapaxar ()
AHA video: Intracoronary abciximab not more effective than IV delivery ()
AHA: ISAR-REACT 4 results may boost bivalirudins uptake ()
AHA video: ATLAS-ACS: Are thrombins a better target than platelets? ()
TCT: Rotablation fails to best balloon angio, but still has merit ()
TCT: Non-inferiority trial shows Synergy DES delivers ()
TCT: Study finds benefit in proximal balloon protection devices during CAS ()
TCT: Resolute, Xience V produce similar results in face-off ()
TCT: TAVIs cost effectiveness depends on approach ()
TCT: Coronary thrombectomy shows no reduction in infarct size ()
TCT: Cath lab staff must integrate, not separate ()
TCT: Most TAVR patients have better quality of life than surgical patients ()
TCT: PARTNER B mortality benefits hold up at two years, as do high stroke rates ()
TCT: Terminated STACCATO trial draws flak ()
TCT: RIFLE aims to make radial approach standard for STEMI ()
TCT: CABG gains on PCI for cost benefits in high-risk patients ()
TCT: Dabi, roxy and apixaban--when is warfarin still useful? ()
TCT: Platelet function bounce-back time is shorter with Plavix than Effient ()
TCT: Cangrelor may fill unmet need for some patients undergoing surgery ()
TCT: Only 2% of post-PCI patients stop dual-antiplatelet therapy at 30 days ()
TCT: CT for chronic total occlusion guidance may be feasible, but should it be used? ()
JAMA: Docs who bill for cardiac stress tests more likely to order them ()
TCT: Is TAVI cost effective? U.K. analysis says yes ()
TCT Feature: Impella comes in under $100k threshold ()
Amylin, Lilly end diabetes partnership ()
TCT Feature: Not so fast! Left-main PCI is only appropriate for minority ()
TCT: Regulatory process, costs drive medical innovation out of the U.S. ()
TCT Feature: Resolute may resolve bad outcomes for diabetics ()
Feature: New ACC/AHA guidelines on PCI emphasize collaboration ()
TCT Feature: Impella may help thwart CV events in sicker patients ()
JACR: Communication breakdowns add to growing malpractice costs ()
NESCE panel: Where is clinical engineering headed? ()
Circ: Newer LVAD costs drop but miss effectiveness mark ()
Feature: Fibrinolysis for transferred STEMIs produces good outcomes ()
FDA approves Xarelto for AF stroke prevention ()
FDA approves first transcatheter aortic heart valve; ACC president responds ()
NEJM: ADHD drugs not associated with adverse cardiac events ()
AIM: Dual-antiplatelet therapy may work; anticoagulants may be better ()
Feature: CRF, Boston angio labs partner to improve clinical trial process ()
Transcatheter therapies and drug-eluting balloons are hot topics at TCT ()
CHIME: The difficult life after CPOE, EHR go-live ()